Sanaria
Sanaria

AWARDS

  • 2015 - Montgomery County Bioscience Company of the Year - Montgomery County Small Business Awards
  • 2015 - CEO of the year - World Vaccine Congress, Vaccine Industry Excellence Awards
  • 2015 - CEO of the year - Tech Council of Maryland, Annual Industry Awards
  • 2014 - Best Prophylactic Vaccine - World Vaccine Congress, Vaccine Industry Excellence Awards
  • 2013 - Emerging Business of the Year - Montgomery County Chamber of Commerce
  • 2012 - Commercialization Award - Maryland Biotech Center
  • 2011 - Biotechnology Firm of the Year - Tech Council of Maryland
  • 2011 - Executive of the Year - Tech Council of Maryland Tech Awards
  • 2010 - Innovator of the Year - The Daily Record
  • 2010 - Ranked 15th in The Gazette of Politics and Business Exceptional 53 Business Award
  • 2009 - Best Early-Stage Vaccine Biotech - Vaccine Congress Washington, Vaccine Industry Excellence Awards
  • 2009 - Ranked 22nd in The Gazette of Politics and Business Exceptional 53 Business Award
  • 2008 - Emerging Company of the Year - Tech Council of Maryland Tech Awards

PRESS

PRESS RELEASES

  • May 9, 2016:Sanaria's Malaria Vaccine Yields Unprecedented Protection In Clinical Trial
  • June 29, 2015:Government Of Equatorial Guinea And Oil Companies Agree To $48.5 Million Funding Of Malaria Vaccine Development Program With Sanaria Inc.
  • April 30, 2014:Sanaria Inc. to launch crowdfunding campaign for SporoBot, a mosquito-dissecting robot for accelerating manufacture of Sanaria's malaria vaccine
  • March 2014:Sanaria PfSPZ Malaria Vaccine Wins 2014 Vaccine Industry Excellence Award for 'Best Prophylactic Vaccine'
  • August 8, 2013:Sanaria's Malaria Vaccine Yields Unprecedented Protection In Phase 1 Clinical Trial
  • June 13, 2012:Sanaria and the Institute for Bioscience and Biotechnology Research of the University of Maryland College Park Awarded Collaborative, US $3M NIH Phase II Small Business Innovation Research Grant
  • September 8, 2011: Science publishes Sanaria's Research Article, Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8+ T Cell Immunity
  • June 29, 2011: Sanaria announces the launch of its Sanaria® Family of Products and Services intended to advance research towards new malaria vaccines, drugs, and diagnostics, and enhanced understanding of malaria pathology and immunobiology
  • February 23, 2010: Sanaria Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research grant to develop a genetically attenuated whole parasite malaria vaccine
  • February 19, 2010: Medicine in Need (MEND) receives $3 million grant from the Bill and Melinda Gates Foundation to apply advanced formulation technologies to the stabilization of new malaria vaccine candidates, including Sanaria's PfSPZ vaccine
  • September 16, 2009: Sanaria receives multi-year U.S. NIH phase II Small Business Innovation Research grant to enhance efficiency and scale-up of its malaria vaccine manufacturing process
  • June 2, 2009: Sanaria receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
  • April 23, 2009: Sanaria and PATH-MVI announce that Phase 1 trial of Sanaria's whole-parasite malaria vaccine called PfSPZ Vaccine to begin; FDA approval for testing in humans watershed moment for unique malaria vaccine approach
  • October 30, 2008: Sanaria and TI Pharma collaborators at Radboud University Nijmegen Medical Centre and Leiden University Medical Centre publish the first report of genetically attenuated P. falciparum sporozoites
  • July 29, 2008: Sanaria and the University of Maryland Biotechnology Institute awarded collaborative, multi-year, US $600,000 NIH SBIR grant
  • May 15, 2008: Sanaria named Maryland's Emerging Company of the Year at the annual Technology Council of Maryland's Tech Awards Celebration
  • January 16, 2008: Sanaria, Top Institute Pharma, Radboud University Nijmegen Medical Centre and Leiden University Medical Center enter into $23.6 million research agreement
  • October 26, 2007: Sanaria, PATH Malaria Vaccine Initiative Open Manufacturing Facility For Producing World's First "Whole-Parasite" Malaria Vaccine
  • January 29, 2007: Sanaria Inc. Receives Multi-Year $3.47 Million U.S. NIH Phase I and Phase II Small Business Innovation Research Grants to Enhance Development of its Malaria Vaccine
  • December 14, 2006: PATH Malaria Vaccine Initiative Announces New Partnership To Accelerate Development of Novel Malaria Vaccine Candidate MVI and Sanaria Inc. to Conduct Initial Safety and Test-of-Concept Trial
  • March 19, 2006: Sanaria CEO, Dr. Stephen L. Hoffman, is the most cited author in the world
  • June 20, 2005: Sanaria Receives NIAID (NIH) award for Development of its Malaria Vaccine
  • May 2, 2005: Sanaria Receives U.S. Army Award for Development of its Malaria Vaccine
  • October 20, 2004: Dr. Stephen L. Hoffman Elected to Membership in the Institute of Medicine of National Academies
  • July 13, 2004: The Institute for One World Health and Sanaria

RELEVANT PUBLICATIONS

NEWS

  • June 2016 - Sanaria's CEO, Dr. Stephen L. Hoffman, awarded the 2016 Weill Cornell Medicine Alumni Association Award of Distinction for his significant accomplishments as a physician, scientist and entrepreneur; Commencement Speech
  • May 2016 - Nature Medicine publishes Sanaria's Research Article, Protection against malaria at 1 year and immune correlates following PfSPZ vaccination; Abstract
  • June 2015 - Sanaria wins 2015 Montgomery County Bioscience Company of the Year at the 3rd Annual Montgomery County Small Business Awards; Learn More
  • June 2015 - The Government of the Republic of Equatorial Guinea announced a $48.5M support agreement with its oil sector partners, Marathon Oil, Noble Energy Inc. and AMPCO, to sponsor the clinical development of Sanaria PfSPZ Vaccine against malaria, including a series of clinical trials from 2015 through 2018 Press Release
  • April 2015 - Sanaria's Executive VP of Manufacturing and Process Development, Dr. B. Kim Lee Sim, featured in Malaymail Online Article: The Nyonya who is saving the world from malaria
  • April 2015 - Dr. Stephen L. Hoffman wins 2015 CEO of the year at the World Vaccine Congress, Vaccine Industry Excellence Awards; Learn More
  • March 2015 - First clinical trial of new malaria vaccine held in Equatorial Guinea; News Medical
  • February 2015 - Cryoport and Sanaria Expand Logistics Partnership Supporting Malaria Vaccines distributed in Liquid Nitrogen Vapor Phase; Press Release
  • September 2014 - Sanaria's CEO & CSO, Dr. Stephen L. Hoffman, ranked 3rd out of the 50 most influential people in vaccines behind Bill Gates and Dr. Thomas Monath; 50 most influential
  • August 2014 - Sanaria recognized as a NIH SBIR/STTR Notable Succes; Learn More
  • July 2014 - First controlled human malaria infection in Africa shows that PfSPZ Challenge can be used for drug and vaccine development in the field; American Society of Tropical Medicine and Hygiene's Press Release
  • July 2014 - GSK submitted a regulatory application to the European Medicines Agency for its malaria vaccine candidate, RTS,S. Sanaria and GSK's different approaches explained in WSJ article
  • March 2014 - Sanaria wins Best Prophylactic Vaccine at the 2014 World Vaccine Congress, Vaccine Industry Excellence Awards; Press Release
  • January 2014 - Diosdado Vicente Nsue Milang, Equatorial Guinea's Minister of Health and Social Welfare Discusses Sanaria's Malaria Vaccine Clinical Trial video
  • January 2014 - Sanaria's Vice President International Projects and Strategy, Dr. Peter F. Billingsley, featured in Queen's University Alumni Review, Biology Grad Helping Develop Breakthrough Malaria Vaccine
  • October 2013 - Sanaria's CEO, Dr. Stephen L. Hoffman, featured in Washingtonian Magazine, Dr. Hoffman vs. the Mosquito
  • October 2013 - Sanaria is a proud sponsor of Frontiers in Science and Medicine Day 2013
  • October 2013 - The Government of Equatorial Guinea announces a plan to work with Sanaria and its partners, Marathon and Medical Care Development International, to develop a program to use Sanaria's malaria vaccine to combat malaria on Bioko Island; Press Release
  • August 2013 - Sanaria CEO, Dr. Stephen L. Hoffman answered questions about the SANARIA PfSPZ Vaccine on Reddit's AMA
  • August 2013 - Science publishes Sanaria's Research Article, Protection Against Malaria by Intravenous Immunization with a Non-Replicating Sporozoite Vaccine; Abstract
  • March 2013 - Sanaria's CEO & CSO, Dr. Stephen L. Hoffman, ranked 21st out of the 50 most influential people in vaccines; 50 most influential
  • January 2013 - In collaboration with the Radboud University Nijmegen Medical Center, a high level of controlled human malaria infection (CHMI) was achieved with Sanaria® PfSPZ Challenge paving the way towards the elimination of the need for live mosquito bites to test anti-malarial vaccines and drugs; AJTMH, Healio
  • January 2013 - Sanaria Sr. Director, Dr. Eric James, publishes in Vaccine; Comparative cost models of a liquid nitrogen vapor phase (LNVP) cold chain-distributed cryopreserved malaria vaccine vs. a conventional vaccine
  • January 2013 - Dr. Judith E. Epstein publishes in AJTMH; Taking a Bite out of Malaria: Controlled Human Malaria Infection by Needle and Syringe
  • January 2013 - Sanaria featured in the BBC's news story, A Faster Path to a Possible Malaria Vaccine
  • October 2012 - Sanaria is a proud sponsor of Frontiers in Science and Medicine Day 2012
  • June 2012 - Sanaria and the Institute for Bioscience and Biotechnology Research of the University of Maryland College Park Awarded Collaborative, US $3M NIH Phase II Small Business Innovation Research Grant
  • January 2012 - The Sanaria®PfSPZ Vaccine is being assessed in a clinical trial at the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  • October 2011 - Sanaria is a proud sponsor of Frontiers in Science and Medicine Day 2011
  • September 2011 - Science publishes Sanaria's Research Article, Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8+ T Cell Immunity
  • April 2011 - Sanaria and Sanaria's CEO, Dr. Stephen L. Hoffman, were nominated as one of the Tech Council of Maryland's three finalists for the 2011 Tech Awards for Biotechnology Firm of the Year and Executive of the Year, respectively
  • March 2011 - Sanaria is proud to announce the appointment of Peter F. Billingsley, PhD, Senior Director of Entomology and Quality Systems, to the Editorial Board of the Malaria Journal; more information
  • December 2010 - Bill Shore appeared on Good Morning America to discuss his book The Imaginations of Unreasonable Men: Inspiration, Vision and Purpose in the Quest to End Malaria, featuring Sanaria's CEO Dr. Stephen L. Hoffman and Sanaria Inc.; video
  • December 2010 - Sanaria, in collaboration with the Walter Reed Army Institute of Research and the Center for Disease Control/National Center for Infectious Disease, publish research results in PLoS ONE; Establishment of an In Vitro Assay for Assessing the Effects of Drugs on the Liver Stages of Plasmodium vivax Malaria
  • October 2010 - Sanaria, in collaboration with the University of Maryland School of Medicine and Protein Potential, LLC, publish clinical trial results in PLoS ONE; Plasmodium falciparum Malaria Challenge by the Bite of Aseptic Anopheles stephensi Mosquitoes: Results of a Randomized Infectivity Trial
  • September 2010 - Sanaria honored to be ranked 15th among all Maryland businesses in The Gazette of Politics and Business Exceptional 53 Business Awards; P & B 53
  • August 2010 - Sanaria and Sanaria's CEO, Dr. Stephen L. Hoffman, featured in Mental Floss magazine article, The Quest for a Malaria Vaccine and the Man Who Risked Everything to Find It; mentalfloss.com
  • August 2010 - Sanaria's Chief Executive and Scientific Officer, Dr. Stephen L. Hoffman won the Daily Record's Innovator of the Year Award; The Daily Record
  • August 2010 - Sanaria recognized by U.S. Representative Chris Van Hollen for using Recovery Act funding to retain employees and continue its focus on developing a malaria vaccine; POLITICO
  • January 2010 - Dr. David Dolberg, Sanaria's Director of Intellectual Property, is recognized for his contributions to paradigm changing research in cancer; more information
  • January 2010 - Sanaria featured in Volume 6, Issue 1, the January cover, of the Human Vaccines Journal
  • September 2009 - Sanaria ranked 22nd in The Gazette of Politics and Business Exceptional 53 Business Award; Announcement
  • September 2009: Sanaria receives multi-year U.S. NIH phase II Small Business Innovation Research grant to enhance efficiency and scale-up of its malaria vaccine manufacturing process; Press Release
  • July 2009: Sanaria and Sanaria's CEO, Dr. Stephen L. Hoffman, featured in U.S. News and World Report article, Why a Man Let 2,000 Malaria-Infected Mosquitoes Bite Him; usnews.com
  • June 2009: Sanaria featured in Associated Press article, Pulling malaria from mosquitoes to fight disease
  • April 2009: Sanaria and PATH-MVI announce that Phase 1 trial of Sanaria's whole-parasite malaria vaccine called PfSPZ Vaccine to begin; FDA approval for testing in humans watershed moment for unique malaria vaccine approach; Press Release
  • April 2009: Sanaria wins VIE Award for Best Early-Stage Vaccine Biotech at the World Vaccine Congress Washington; ViE; Press Release
  • December 2008: Sanaria and Sanaria's CEO, Dr. Stephen L. Hoffman, featured in Esquire magazine
  • July 2008: Sanaria and TI Pharma collaborators publish the first report of genetically attenuated Pf sporozoites; PLoS ONE; Press Release
  • July 2008 Sanaria and the Univ of Maryland Biotechnology Institute awarded collaborative, multi-year, US $600,000 NIH SBIR grant Press Release
  • May 2008: Sanaria named Emerging Company of the Year at the TCM's Tech Awards; TCM; Press Release; Gazette.net
  • March 2008: Sanaria featured in Scientific American; Scientific American
  • January 2008: Sanaria enters into $23.6 million research agreement; Press Release
  • December 2007: Sanaria featured in The New York Times, The Soul of a New Vaccine; and accompanying video, Searching for a Cure for Malaria
  • December 2007: Q & A Session with Sanaria: How to bring a malaria vaccine to market? Larta Institute
  • December 2007: Sanaria CEO, Dr. Stephen L. Hoffman, interviewed on Al Jazeera English's: The Pulse
  • November 2007: Sanaria announced that Adel A. F. Mahmoud, M.D., Ph.D, of the Woodrow Wilson School of Public and International Affairs and The Department of Molecular Biology at Princeton University and former President of Merck Vaccines, was elected to Sanaria's Board of Directors
  • October 2007: Sanaria opens Clinical Manufacturing Facility; Press Release: featured in Reuters
  • October 2007: Fred Binka (Sanaria Advisory Board Member) featured in Newsweek,"Giving Globally: The Search for Solutions"
  • July 2007: Sanaria featured in National Geographic magazine, Bedlam in the Blood, Malaria
  • April 2007: Sanaria featured in BBC documentary
  • June 2007: Sanaria signs agreement with University of Maryland Biotechnology Institute
  • June 2007: Sanaria issued U.S. patent
  • June 2007: Sanaria signs agreement with University of Maryland Biotechnology Institute
  • May 2007: Sanaria finalizes agreement with Columbia University to develop genetically attenuated malaria sporozoite vaccine
  • April 2007: Sanaria receives Phase I SBIR grant from NIAID, NIH
  • November 2006: PATH-Malaria Vaccine Initiative receives $29.3M from the BMGF to support Sanaria’s malaria vaccine development efforts
  • November 2006: Sanaria CEO receives award for malariology from American Society of Tropical Medicine and Hygiene
  • October 2006: Sanaria CEO receives honorary doctoral degree from Monmouth University
  • September 2006: Sanaria receives Phase II SBIR grant from NIAID, NIH

 

disclaimer     site map

copyright(c) 2003-2016, Sanaria Inc., all rights reserved

Denver web designer